Literature DB >> 12454142

Optimization and evaluation of a PCR assay for detecting toxoplasmic encephalitis in patients with AIDS.

Priya Joseph1, Maritza M Calderón, Robert H Gilman, Monica L Quispe, Jaime Cok, Eduardo Ticona, Victor Chavez, Juan A Jimenez, Maria C Chang, Martín J Lopez, Carlton A Evans.   

Abstract

Toxoplasma gondii is a common life-threatening opportunistic infection. We used experimental murine T. gondii infection to optimize the PCR for diagnostic use, define its sensitivity, and characterize the time course and tissue distribution of experimental toxoplasmosis. PCR conditions were adjusted until the assay reliably detected quantities of DNA derived from less than a single parasite. Forty-two mice were inoculated intraperitoneally with T. gondii tachyzoites and sacrificed from 6 to 72 h later. Examination of tissues with PCR and histology revealed progression of infection from blood to lung, heart, liver, and brain, with PCR consistently detecting parasites earlier than microscopy and with no false-positive results. We then evaluated the diagnostic value of this PCR assay in human patients. We studied cerebrospinal fluid and serum samples from 12 patients with AIDS and confirmed toxoplasmic encephalitis (defined as positive mouse inoculation and/or all of the Centers for Disease Control clinical diagnostic criteria), 12 human immunodeficiency virus-infected patients with suspected cerebral toxoplasmosis who had neither CDC diagnostic criteria nor positive mouse inoculation, 26 human immunodeficiency virus-infected patients with other opportunistic infections and no signs of cerebral toxoplasmosis, and 18 immunocompetent patients with neurocysticercosis. Eleven of the 12 patients with confirmed toxoplasmosis had positive PCR results in either blood or cerebrospinal fluid samples (6 of 9 blood samples and 8 of 12 cerebrospinal fluid samples). All samples from control patients were negative. This study demonstrates the high sensitivity, specificity, and clinical utility of PCR in the diagnosis of toxoplasmic encephalitis in a resource-poor setting.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454142      PMCID: PMC154600          DOI: 10.1128/JCM.40.12.4499-4503.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Limited value of PCR for detection of Toxoplasma gondii in blood from human immunodeficiency virus-infected patients.

Authors:  C Franzen; M Altfeld; P Hegener; P Hartmann; G Arendt; H Jablonowski; J Rockstroh; V Diehl; B Salzberger; G Fätkenheuer
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

2.  Multiplex PCR for diagnosis of AIDS-related central nervous system lymphoma and toxoplasmosis.

Authors:  T C Roberts; G A Storch
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

3.  SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS.

Authors:  D J Skiest; W Erdman; W E Chang; O K Oz; A Ware; J Fleckenstein
Journal:  J Infect       Date:  2000-05       Impact factor: 6.072

4.  Diagnosis of Toxoplasma parasitemia in patients with AIDS by gene detection after amplification with polymerase chain reaction.

Authors:  G A Filice; J A Hitt; C D Mitchell; M Blackstad; S W Sorensen
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

5.  Value of PCR for evaluating occurrence of parasitemia in immunocompromised patients with cerebral and extracerebral toxoplasmosis.

Authors:  A Roth; B Roth; K N Arasteh; K Janitschke
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

6.  Toxoplasma gondii antibodies in pregnant women and their newborns in Dar es Salaam, Tanzania.

Authors:  E Doehring; I Reiter-Owona; O Bauer; M Kaisi; H Hlobil; G Quade; N A Hamudu; H M Seitz
Journal:  Am J Trop Med Hyg       Date:  1995-06       Impact factor: 2.345

7.  Congenital toxoplasmosis: an experimental study in rhesus monkeys for transmission and prenatal diagnosis.

Authors:  E Schoondermark-Van de Ven; W Melchers; J Galama; W Camps; T Eskes; J Meuwissen
Journal:  Exp Parasitol       Date:  1993-09       Impact factor: 2.011

8.  Potential of the polymerase chain reaction in the diagnosis of active Toxoplasma infection by detection of parasite in blood.

Authors:  E C Guy; D H Joynson
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

9.  Detection of Toxoplasma gondii by PCR and tissue culture in cerebrospinal fluid and blood of human immunodeficiency virus-seropositive patients.

Authors:  M Dupon; J Cazenave; J L Pellegrin; J M Ragnaud; A Cheyrou; I Fischer; B Leng; J Y Lacut
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

10.  Detection of circulating antigens of Toxoplasma gondii in human infection.

Authors:  J Hafid; R Tran Manh Sung; H Raberin; Z Y Akono; B Pozzetto; M Jana
Journal:  Am J Trop Med Hyg       Date:  1995-04       Impact factor: 2.345

View more
  19 in total

1.  Comparison of two widely used PCR primer systems for detection of toxoplasma in amniotic fluid, blood, and tissues.

Authors:  Elisabeth Chabbert; Laurence Lachaud; Lucien Crobu; Patrick Bastien
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

2.  Diagnosis of cerebral toxoplasmosis by detection of Toxoplasma gondii tachyzoites in cerebrospinal fluid.

Authors:  C Palm; H Tumani; T Pietzcker; D Bengel
Journal:  J Neurol       Date:  2008-04-30       Impact factor: 4.849

3.  Diagnosis of cerebral toxoplasmosis in AIDS patients in Brazil: importance of molecular and immunological methods using peripheral blood samples.

Authors:  Fabio A Colombo; José E Vidal; Augusto C Penalva de Oliveira; Adrián V Hernandez; Francisco Bonasser-Filho; Roberta S Nogueira; Roberto Focaccia; Vera Lucia Pereira-Chioccola
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Development and padronization of three multiplex PCRs for the diagnosis of Chlamydia trachomatis, Toxoplasma gondii, herpes simplex viruses 1 and 2, and Cytomegalovirus.

Authors:  Danielle A G Zauli; Carla Lisandre Paula de Menezes; Cristiane Lommez de Oliveira
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

Review 5.  Parasitic central nervous system infections in immunocompromised hosts.

Authors:  Melanie Walker; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-03-02       Impact factor: 9.079

Review 6.  Molecular methods for diagnosis of viral encephalitis.

Authors:  Roberta L Debiasi; Kenneth L Tyler
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  PCR assay using cerebrospinal fluid for diagnosis of cerebral toxoplasmosis in Brazilian AIDS patients.

Authors:  José E Vidal; Fabio Antonio Colombo; Augusto C Penalva de Oliveira; Roberto Focaccia; Vera Lucia Pereira-Chioccola
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

8.  Evaluation of a PCR assay for diagnosis of toxoplasmosis in serum and peripheral blood mononuclear cell among HIV/AIDS patients.

Authors:  Farah Bokharaei-Salim; Abdoulreza Esteghamati; Khadijeh Khanaliha; Saeed Kalantari; Shirin Sayyahfar; Tahereh Donyavi; Saba Garshasbi; Qasem Asgari; Borna Salemi
Journal:  J Parasit Dis       Date:  2019-12-11

9.  Molecular diagnosis of Toxoplasma gondii infection in cerebrospinal fluid from AIDS patients.

Authors:  Yenisey Alfonso; Jorge Fraga; Carlos Fonseca; Narciso Jiménez; Taimy Pinillos; Alberto J Dorta-Contreras; Raymundo Cox; Virginia Capó; Olga Pomier; Francisco Bandera; Dora Ginorio
Journal:  Cerebrospinal Fluid Res       Date:  2009-03-06

10.  Real-time RT-PCR on SAG1 and BAG1 gene expression during stage conversion in immunosuppressed mice infected with Toxoplasma gondii Tehran strain.

Authors:  Monavar Selseleh; Mohammad Hossein Modarressi; Mehdi Mohebali; Saeedeh Shojaee; Mohammad Reza Eshragian; Mina Selseleh; Ebrahim Azizi; Hossein Keshavarz
Journal:  Korean J Parasitol       Date:  2012-08-13       Impact factor: 1.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.